Article Text
Abstract
Introduction To evaluate WHO chest radiograph interpretation processes during a pneumococcal vaccine effectiveness study of children aged 3–35 months with suspected pneumonia in Sylhet, Bangladesh.
Methods Eight physicians masked to all data were standardised to WHO methodology and interpreted chest radiographs between 2015 and 2017. Each radiograph was randomly assigned to two primary readers. If the primary readers were discordant for image interpretability or the presence or absence of primary endpoint pneumonia (PEP), then another randomly selected, masked reader adjudicated the image (arbitrator). If the arbitrator disagreed with both primary readers, or concluded no PEP, then a masked expert reader finalised the interpretation. The expert reader also conducted blinded quality control (QC) for 20% of randomly selected images. We evaluated agreement between primary readers and between the expert QC reading and the final panel interpretation using per cent agreement, unadjusted Cohen’s kappa, and a prevalence and bias-adjusted kappa.
Results Among 9723 images, the panel classified 21.3% as PEP, 77.6% no PEP and 1.1% uninterpretable. Two primary readers agreed on interpretability for 98% of images (kappa, 0.25; prevalence and bias-adjusted kappa, 0.97). Among interpretable radiographs, primary readers agreed on the presence or absence of PEP in 79% of images (kappa, 0.35; adjusted kappa, 0.57). Expert QC readings agreed with final panel conclusions on the presence or absence of PEP for 92.9% of 1652 interpretable images (kappa, 0.75; adjusted kappa, 0.85).
Conclusion Primary reader performance and QC results suggest the panel effectively applied the WHO chest radiograph criteria for pneumonia.
- Asia
- developing countries
- respiratory tract diseases
- child
- infant
- pneumococcal vaccines
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
Footnotes
Contributors Funding acquisition: AHB and EDM. Conceptualisation and design: EDM and AHB. Data curation: EDM, AHB, NHC and SJR. Data collection: EDM, SA, AMK, ADR, AAH, ANUA, EHF, MM, MMH, FD, BT and FA. Data analysis: EDM, NHC, SJR, HBS, NS and LHM. Data interpretation: EDM, AHB, FP, NS, MER, MH, HBS, MS, LHM and WC. Writing—original draft: EDM. Writing—review & editing: EDM, AHB, WC, LHM, MS, SA, NB, SKS, AQ, HBS, MH, MER, NS, FA, BT, FD, MMH, MM, EHF, ANUA, FP, AAH, ADR, AMK, AJR and NHC.
Funding This study is funded by the Bill & Melinda Gates Foundation [OPP1084286, OPP1117483] and GlaxoSmithKline [90063241]. EDM was also supported by the Fogarty International Center of the National Institutes of Health under Award Number K01TW009988 for the research reported in this publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Bill & Melinda Gates Foundation, GlaxoSmithKline or the National Institutes of Health.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.